DNLI (Denali Therapeutics) EBIT per Share : $-3.07 (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Denali Therapeutics EBIT per Share?

Denali Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-0.76. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.07.

During the past 3 years, the average EBIT per Share Growth Rate was -7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Denali Therapeutics's EBIT per Share or its related term are showing as below:

DNLI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -69.4 Med: -6.8 Max: 55.1
Current: -7.8

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Denali Therapeutics was 55.10% per year. The lowest was -69.40% per year. And the median was -6.80% per year.

DNLI's 3-Year EBIT Growth Rate is ranked worse than
65.33% of 1223 companies
in the Biotechnology industry
Industry Median: 3.1 vs DNLI: -7.80

Denali Therapeutics's EBIT for the three months ended in Dec. 2024 was $-129.8 Mil.

Denali Therapeutics EBIT per Share Historical Data

The historical data trend for Denali Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics EBIT per Share Chart

Denali Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

0.56

-2.43

-2.71

-1.43

-3.05

Denali Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.96	-0.89	-0.69	-0.73	-0.76

Denali Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Denali Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-501.878	/	164.474
=	-3.05

Denali Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-129.846	/	170.127
=	-0.76

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.07

Denali Therapeutics (NAS:DNLI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Denali Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

4DN:Germany

Address

161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.denalitherapeutics.com

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Executives

Carole Ho	officer: Chief Medical Officer	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Alexander O. Schuth	officer: COO and Secretary	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes	officer: CFO and Treasurer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Ryan J. Watts	director, officer: President and CEO	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jennifer E. Cook	director	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne	director	1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris	director	60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton	10 percent owner	201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Clinton Bybee	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert Nelsen	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631